Substance / Medication

Travoprost

Overview

Active Ingredient
travoprost
RxNorm CUI
283809

Indications

® iDoseTR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Labeler: Glaukos CorporationUpdated: 2026-02-04T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

47 trials linked to this intervention

47
Total Trials
0
Recruiting
27
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of travoprost for the treatment of patients with glaucoma.
Zhang Xiu-Li, Qin Li · Medicine (Baltimore) · 2019
PMID: 31335731Meta-AnalysisFull text (PMC)
Comparison between Latanoprost, Travoprost, and Tafluprost in reducing intraocular pressure fluctuations in patients with glaucoma.
Faseeh Ahmed Essam, Allam Riham Shm, Shalash Ahmed B et al. · Eur J Ophthalmol · 2021
PMID: 33499676RCT
The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP.
Guven Yilmaz Suzan, Degirmenci Cumali, Karakoyun Yunus Emre et al. · Int Ophthalmol · 2018
PMID: 28616797RCT
The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma.
Shin Jonghoon, Lee Ji-Woong, Choi Beom-Seok et al. · J Ocul Pharmacol Ther · 2014
PMID: 25285367RCT
[Clinical efficacy of travoprost-timolol fixed combination on ocular hypotensive agents and ocular surface agents in Japanese glaucoma patients].
Kanamoto Takashi, Kiuchi Yoshiaki, Ichioka Ikuko et al. · Nippon Ganka Gakkai Zasshi · 2013
PMID: 24354263RCT
Dose response for travoprost® in the glaucomatous beagle.
Mackay Edward O, McLaughlin Marsha, Plummer Caryn E et al. · Vet Ophthalmol · 2012
PMID: 22050687RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Travoprost (substance)
SNOMED CT
129493000
UMLS CUI
C0937916
RxNorm CUI
283809
Labeler
Glaukos Corporation

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
47
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.